Novartis AG (NVS)
103.84
+0.74
(+0.72%)
USD |
NYSE |
Nov 21, 16:00
103.80
-0.04
(-0.03%)
After-Hours: 20:00
Novartis PS Ratio: 4.264 for Nov. 21, 2024
PS Ratio Chart
Historical PS Ratio Data
| Date | Value |
|---|---|
| November 20, 2024 | 4.233 |
| November 19, 2024 | 4.241 |
| November 18, 2024 | 4.231 |
| November 15, 2024 | 4.232 |
| November 14, 2024 | 4.246 |
| November 13, 2024 | 4.265 |
| November 12, 2024 | 4.308 |
| November 11, 2024 | 4.339 |
| November 08, 2024 | 4.371 |
| November 07, 2024 | 4.397 |
| November 06, 2024 | 4.386 |
| November 05, 2024 | 4.492 |
| November 04, 2024 | 4.538 |
| November 01, 2024 | 4.490 |
| October 31, 2024 | 4.451 |
| October 30, 2024 | 4.513 |
| October 29, 2024 | 4.539 |
| October 28, 2024 | 4.748 |
| October 25, 2024 | 4.673 |
| October 24, 2024 | 4.646 |
| October 23, 2024 | 4.684 |
| October 22, 2024 | 4.694 |
| October 21, 2024 | 4.752 |
| October 18, 2024 | 4.812 |
| October 17, 2024 | 4.784 |
| Date | Value |
|---|---|
| October 16, 2024 | 4.787 |
| October 15, 2024 | 4.772 |
| October 14, 2024 | 4.776 |
| October 11, 2024 | 4.772 |
| October 10, 2024 | 4.715 |
| October 09, 2024 | 4.749 |
| October 08, 2024 | 4.672 |
| October 07, 2024 | 4.676 |
| October 04, 2024 | 4.679 |
| October 03, 2024 | 4.672 |
| October 02, 2024 | 4.701 |
| October 01, 2024 | 4.704 |
| September 30, 2024 | 4.723 |
| September 27, 2024 | 4.881 |
| September 26, 2024 | 4.881 |
| September 25, 2024 | 4.915 |
| September 24, 2024 | 4.915 |
| September 23, 2024 | 4.913 |
| September 20, 2024 | 4.895 |
| September 19, 2024 | 4.896 |
| September 18, 2024 | 4.896 |
| September 17, 2024 | 4.885 |
| September 16, 2024 | 4.937 |
| September 13, 2024 | 4.883 |
| September 12, 2024 | 4.885 |
Price to Sales Ratio Definition
The Price to Sales Ratio (PS Ratio) is calculated by taking the stock price / revenue per share (ttm). This metric is considered a valuation metric that confirms whether the sales of a company justifies the stock price. There isn't necesarily an optimum PS ratio, since different industries will have different ranges of PS Ratios. Because of this, PS Ratio is great to evaluate from a relative standpoint with other similar companies. PS Ratio might also be a handy metric for companies that are not profitable yet, since they might be valued moreso by their overall sales and potential of becoming profitable in the future.
PS Ratio Range, Past 5 Years
3.186
Minimum
Mar 23 2020
5.104
Maximum
Aug 30 2024
4.131
Average
4.125
Median
Nov 01 2022
PS Ratio Benchmarks
| AstraZeneca PLC | 3.921 |
| Johnson & Johnson | 4.305 |
| Eli Lilly and Co | 16.59 |
| Novo Nordisk AS | 11.65 |
| Monte Rosa Therapeutics Inc | -- |
PS Ratio Related Metrics
| PE Ratio | 12.17 |
| PEG Ratio | 0.0942 |
| Price to Book Value | 4.792 |
| Price to Free Cash Flow | 17.03 |
| Price | 103.84 |
| Earnings Yield | 8.21% |
| Market Cap | 207.59B |
| PEGY Ratio | 0.0916 |
| Operating PE Ratio | 15.66 |
| Normalized PE Ratio | 18.09 |